Trademark: 79268366
Word
NEUVIS
Status
Dead
Status Code
602
Status Date
Thursday, August 4, 2022
Serial Number
79268366
Mark Type
4000
Filing Date
Wednesday, July 31, 2019
Abandoned Date
Friday, July 22, 2022

Trademark Owner History

Classifications
5 Pharmaceutical preparations, namely, pharmaceutical preparations for prevention, management or treatment of inflammatory disorders, neurological disorders, psychiatric disorders, malignancy, immune disorders, metabolic disorders, infectious diseases, gastrointestinal disorders, cardiovascular disorders, cancer, pain; Pharmaceutical preparations derived from natural sources namely, plants, herbs, and flowers for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's disease, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavior modification, schizophrenia, bi-polar disorder, pain; Veterinary preparations derived from natural sources namely, plants, herbs, and flowers for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Plant extracts for medical, pharmaceutical and veterinary use; Biochemical and biological products, in the nature of terpenophenolics, terpenoids and flavones for medical and pharmaceutical use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavioural modification, schizophrenia, bi-polar, pain; Biochemical and biological products, namely, terpenophenolics, terpenoids and flavones for veterinary use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Chemical preparations for medical and pharmaceutical use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavioural modification, schizophrenia, bi-polar, pain; Chemical preparations for veterinary use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Chemical products, namely, aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, arylsulfonamides, eicosanoids for medical and pharmaceutical use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavioural modification, schizophrenia, bi-polar, pain; Chemical products, namely, aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, arylsulfonamides, eicosanoids for veterinary use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Analgesic preparations; Anti-inflammatory preparations; Anti-microbial preparations for inhibiting microbiological growth and infection in medical and veterinary situations; Anti-nauseants treatment preparations; Anti-spasmodics; Anticonvulsants; Appetite stimulant preparations for medical purposes; Nausea medications, namely, nausea treatment preparations

Trademark Events
Aug 27, 2023
Final Decision Transaction Processed By Ib
Aug 4, 2023
Final Disposition Notice Sent To Ib
Aug 4, 2023
Final Disposition Notice Created, To Be Sent To Ib
Aug 4, 2022
Abandonment Notice E-Mailed - Failure To Respond
Aug 4, 2022
Abandonment Notice Mailed - Failure To Respond
Aug 4, 2022
Abandonment - Failure To Respond Or Late Response
Jan 21, 2022
Notification Of Non-Final Action E-Mailed
Jan 21, 2022
Non-Final Action E-Mailed
Jan 21, 2022
Non-Final Action Written
Oct 15, 2021
Teas/Email Correspondence Entered
Oct 14, 2021
Correspondence Received In Law Office
Oct 14, 2021
Teas Response To Office Action Received
Apr 14, 2021
Notification Of Non-Final Action E-Mailed
Apr 14, 2021
Non-Final Action E-Mailed
Apr 14, 2021
Non-Final Action Written
Mar 20, 2021
Notification Of Possible Opposition - Processed By Ib
Mar 9, 2021
Teas/Email Correspondence Entered
Mar 9, 2021
Correspondence Received In Law Office
Mar 9, 2021
Teas Response To Office Action Received
Mar 3, 2021
Notification Of Possible Opposition Sent To Ib
Mar 3, 2021
Notification Of Possible Opposition Created, To Be Sent To Ib
Sep 26, 2020
Refusal Processed By Ib
Sep 9, 2020
Non-Final Action Mailed - Refusal Sent To Ib
Aug 28, 2020
Refusal Processed By Mpu
Jul 25, 2020
Non-Final Action (Ib Refusal) Prepared For Review
Jul 24, 2020
Non-Final Action Written
Jul 17, 2020
Assigned To Examiner
Nov 5, 2019
Assigned To Examiner
Oct 25, 2019
Assigned To Examiner
Oct 8, 2019
Application Filing Receipt Mailed
Oct 4, 2019
New Application Office Supplied Data Entered
Sep 26, 2019
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24